Interferon therapy reduces incidence of hepatocellular carcinoma in patients with high risk of hepatitis B virus-related hepatocellular carcinoma

doi:10.4251/wjgo.123962

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 18, Issue 11

This Article

(7)

(0)

(202)

Peer-Review Report of This Article

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Oncology

ISSN

1948-5204

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Observational Study

Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.

World J Gastrointest Oncol. Nov 15, 2026; 18(11): 123962
Published online Nov 15, 2026. doi: 10.4251/wjgo.123962

Full Size Figure Download Figure

Figure 4 Changes in hepatocellular carcinoma risk stratification in interferon group and nucleos(t)ide analogs group before and after treatment. A: Changes in the proportion of different risk groups before and after treatment based on Real-world Effectiveness from the Asia Pacific Rim Liver Consortium for hepatitis B virus score; B: Changes in the number of different risk groups before and after treatment based on Real-world Effectiveness from the Asia Pacific Rim Liver Consortium for hepatitis B virus score; C: Changes in the proportion of different risk groups before and after treatment based on age-male-ALBI-platelets score; D: Changes in the number of different risk groups before and after treatment based on age-male-ALBI-platelets score. NAs: Nucleos(t)ide analogs; IFN: Interferon; REAL-B: Real-world Effectiveness from the Asia Pacific Rim Liver Consortium for hepatitis B virus; aMAP: Age-male-ALBI-platelets.

Citation: Hao M, Liu CR, Zhang M, Zhou XQ, Jiang ZC, Gao XH, Zhang X, Wang WJ, Wang YK, Jia XL, Li YP, Dang SS. Interferon therapy reduces incidence of hepatocellular carcinoma in patients with high risk of hepatitis B virus-related hepatocellular carcinoma. World J Gastrointest Oncol 2026; 18(11): 123962
URL: https://www.wjgnet.com/1948-5204/full/v18/i11/123962.htm
DOI: https://dx.doi.org/10.4251/wjgo.123962

Hao M, Liu CR, Zhang M, Zhou XQ, Jiang ZC, Gao XH, Zhang X, Wang WJ, Wang YK, Jia XL, Li YP, Dang SS. Interferon therapy reduces incidence of hepatocellular carcinoma in patients with high risk of hepatitis B virus-related hepatocellular carcinoma. World J Gastrointest Oncol 2026; 18(11): 123962 [DOI: 10.4251/wjgo.123962]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.